Before Your Dermal Filler Treatment Ask This One Vital Question
If you only ask one question before your dermal filler treatment, make sure it's this one. Most patients never ask it. Every patient should.
A word most patients have never heard
Hyaluronidase, also commonly referred to by its original brand name ‘Hyalase’.
It is not a word that comes up in Instagram filler content, in clinic brochures, or in the glossy before-and-after posts that populate aesthetic social media. It is not glamorous. It does not have a hashtag.
But Hyaluronidase (Hyalase) is, arguably the single most important word in dermal filler safety and whether your clinic has it, and knows how to use it, tells you more about the standard of care you are receiving than almost anything else.
Hyaluronidase (Hyalase) is, arguably the single most important word in dermal filler safety and whether your clinic has it, and knows how to use it, tells you more about the standard of care you are receiving than almost anything else.
What is Hyaluronidase (Hyalase) ?
Hyaluronidase is an enzyme that dissolves hyaluronic acid, the substance used in the vast majority of dermal fillers. Injected into the skin, it rapidly breaks down hyaluronic acid filler, reversing its effect. In routine aesthetic practice it is used to correct unsatisfactory results, dissolve filler that has migrated, or address overcorrection. These are useful applications. They are not the reason it matters most.
Why it matters most
The most serious complication of dermal filler treatment is vascular occlusion, the accidental blockage of a blood vessel by injected filler, cutting off blood supply to the tissue it serves. In the worst cases, involving the vessels that supply the eye, this can result in permanent vision loss. Vascular occlusion is rare. It is also time-critical, the window for effective intervention is measured in minutes to hours depending on which vessel is affected.
The treatment for hyaluronic acid filler-induced vascular occlusion is immediate, high-dose hyaluronidase injected into and around the affected area to dissolve the filler and restore blood flow as rapidly as possible. A practitioner who does not have hyaluronidase immediately available cannot begin this treatment without delay. And in a vascular occlusion, delay has consequences that may be permanent.
Read an extended look at Filler-Induced Vascular Occlusion.
What the absence of hyaluronidase tells you
A clinic that does not carry hyaluronidase on site is not prepared for the most serious complication of the treatment they are offering. This is not a minor gap in their equipment list. It is a fundamental failure of clinical preparedness — equivalent to performing a procedure with a known bleeding risk without having the means to manage a bleed.
It also raises a broader question about the clinical framework surrounding the treatment. A practitioner who carries hyaluronidase, knows the signs of vascular occlusion, has a written emergency protocol, and has trained in its management is a practitioner who has taken the risks of filler treatment seriously. One who has not done these things has not, and the hyaluronidase question is the quickest way to find out which you are dealing with.
The question and the answer you want
Before any dermal filler treatment, ask your practitioner directly:
Do you have hyaluronidase on site?
The answer you want is immediate and unequivocal “yes, always”.
Any hesitation, any vagueness, or any suggestion that it is available nearby but not in the clinic, is not the answer you want.
You might also ask whether they have trained in managing vascular occlusion and what their emergency protocol looks like. A practitioner who welcomes these questions and answers them confidently is one who takes their clinical responsibility seriously. One who seems surprised to be asked them is providing important information of a different kind.
At The Cosmetic Doctors Company
Hyaluronidase is always on site. Every filler treatment is performed by an experienced medical doctor who understands the vascular anatomy of the face, recognises the early signs of vascular compromise, and has a clear protocol for managing complications immediately if they arise. We consider this the minimum standard, not a selling point.